NUWE
NASDAQNuwellis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$0.14-0.00 (-3.23%)
01:30 PM07:45 PM
News · 26 weeks57-33%
2025-12-142026-06-07
Mix3690d
- SEC Filings14(39%)
- Other13(36%)
- Insider5(14%)
- Earnings2(6%)
- Offering2(6%)
Latest news
25 items- PRNuwellis Announces Closing of $6.0 Million Registered Public OfferingMINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the closing of a public offering of 1,903,338 shares of its common stock ("Common Stock"), pre-funded warrants to purchase 18,096,662 shares of Common Stock, in each case with accompanying Series C Warrants to purchase up to 60,000,000 shares of Common Stock and Series D Warrants to purchase up to 20,000,000 shares of Common Stock with gross proceeds of approximately $6.0 million. The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying
- SECSEC Form 424B4 filed by Nuwellis Inc.424B4 - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Announces Pricing of $6 Million Public OfferingMINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the "Offering"). The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants. Each of the Series C Warrants and Series D Warrants has an exercise price of $0.30 and will be exercisable for a period of fi
- SECSEC Form S-1MEF filed by Nuwellis Inc.S-1MEF - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form EFFECT filed by Nuwellis Inc.EFFECT - Nuwellis, Inc. (0001506492) (Filer)
- SECAmendment: SEC Form S-1/A filed by Nuwellis Inc.S-1/A - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form FWP filed by Nuwellis Inc.FWP - Nuwellis, Inc. (0001506492) (Subject)
- SECAmendment: SEC Form S-1/A filed by Nuwellis Inc.S-1/A - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form SD filed by Nuwellis Inc.SD - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form S-1 filed by Nuwellis Inc.S-1 - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 10-Q filed by Nuwellis Inc.10-Q - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex LabelMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the successful completion of a recent pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed label expansion of the Aquadex SmartFlow® System to support pediatric patients weighing 5 kg and above. The currently cleared indication is for patients weighing 20 kg and above. "In low-weight pediatric patients, fluid management is highly sensitive and requires careful clinical oversight," said Nuwellis' Director of Clinical Strategy Stuart Goldstein, M.D. "The a
- SECNuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis, Inc. Announces First Quarter 2026 Financial ResultsMINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights: Net sales were $2.4 million, a 26% increase compared to the prior-year periodGross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturingCompleted the acquisition of Rendiatech, adding automated kidney-function monitoring capabilities to the Company's product development portfolioAppointed Carisa Schultz as Chief Financial Officer an
- PRNuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report its financial results for the first quarter ended March 31, 2026 premarket on Tuesday, May 12, 2026. The Company will subsequently host a conference call and webcast at 9:00 AM ET on May 12, 2026 to discuss its financial results and provide an update on the Company's performance. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com or access here. Alternatively, you may listen to the live conference call by dialing 1-800-274-84
- INSIDERSEC Form 4 filed by Director Waller Gregory D4 - Nuwellis, Inc. (0001506492) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcdonald David4 - Nuwellis, Inc. (0001506492) (Issuer)
- INSIDERSEC Form 4 filed by Director Feldshon Archelle Georgiou4 - Nuwellis, Inc. (0001506492) (Issuer)
- INSIDERSEC Form 4 filed by Director Emerson Martin J4 - Nuwellis, Inc. (0001506492) (Issuer)
- SECNuwellis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual MeetingMINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights a case study presented by the University of Iowa Stead Family Children's Hospital at the 46th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), held April 22–25, 2026, in Toronto, Canada. At the event, independent investigators presented poster, "Therapeutic Ultrafiltration to Treat Symptomatic Pediatric Heart Failure," which explored the use of ultrafiltration in a pediatric patient with chemotherapy-induced dilated cardiomyopathy and recu
- PRNuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter TechnologyMINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent covering its novel dual lumen midline catheter technology designed for use in ultrafiltration therapies. This next-generation catheter incorporates advanced design elements to optimize blood flow dynamics during therapy. The technology includes separate withdrawal and infusion lumens with pressure-balancing features that help maintain stable flow and reduce complications associated with fluid removal
- SECNuwellis Inc. filed SEC Form 8-K: Other Events8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring RetreatMINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the start of the event, Nuwellis will attend the ERAS Cardiac Spring Retreat gathering of thought leaders, to discuss best practices and innovation in cardiac surgery care. "AATS is one of the largest congresses in the cardiothoracic arena, and a unique opportunity to showcase our Aquadex technology, and
- PRNuwellis Announces Aquadex Software UpdateMINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience. A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, where small-volume fluid shifts can have a significant clinical impact. "The Aquadex software update reflects our commitment to con
NUWE FAQ
6 questionsWhat does Nuwellis Inc. do?
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria...Where does NUWE stock trade?
Nuwellis Inc. (NUWE) is listed on NASDAQ.What sector and industry is NUWE in?
Nuwellis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about NUWE?
Nuwellis Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $1700.00 price target on 2024-07-29. Recent price targets cluster around $1700.00.What companies are similar to NUWE?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NUWE side-by-side with any of them on Quantisnow.How can I track NUWE on Quantisnow?
Quantisnow aggregates Nuwellis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUWE to receive live email and push alerts on every new disclosure.